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ABSTRACT 
 
EFFECTS OF FAMILY HISTORY OF ALZHEIMER'S DISEASE ON GLUCOSE 
METABOLISM (FDG-PET) AMONG MILD COGNITIVE IMPAIRED PATIENTS: A 
LONGITUDINAL STUDY. 
 
By 
 
NERLINE JACQUES 
 
05/19/2017 
 
 
As life expectancy is increasing, the prevalence of Alzheimer's disease (AD) is expected 
to escalate. However, there are still no specific markers to confirm AD diagnosis, nor effective 
treatment for AD, nor an established way to slow down the rate of degeneration. 
This study aims to first examine the effect of positive AD family history (FH+) on 
cerebral metabolic rate of glucose (CMRglc) over a 5-year period among Mild Cognitive 
Impaired (MCI) subjects. It also assesses whether there are parent gender effects on CMRglc 
when the groups negative family history (FH-) vs paternal family history (FHp) vs maternal 
family history (FHm) are compared. Finally, this paper tests whether there is effect modification 
with APOE4 allele interaction. 
Data are drawn from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database.  
A sample size of 177 subjects with a maximum of 30 observations was used. Wilcoxon rank-sum 
test and Chi-square test had been used to test for baseline differences between FH+ and FH- 
groups for the continuous and categorical variables respectively. To analyze the effects of FH on 
CMRglc, multivariate generalized linear mixed-effects models were used.  
The results showed that, compared to subjects who are FH-, FH+ participants presented 
greater CMRglc decline over the 5-year period after controlling for the other covariates. After 
adding APOE4 in the model, FH+ subjects showed significantly lower glucose metabolism rate 
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compared to FH- participants. The sample did not have enough statistical power to detect any 
parental FH differences. Heritability from FH status for explaining CMRglc decline in MCI 
people is small but statistically significant. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background  
 Alzheimer's disease (AD) is a progressive degenerative disorder that harms the brain’s 
nerve cells resulting in loss of memory and cognitive decline. This disease accounts for around 
70 % of all dementia cases (Liu et al., 2016), and leads to death generally within seven to ten 
years after diagnosis (Villemagne & Chételat, 2016). This type of neurodegenerative dementia 
has traumatic effects on not only the person suffering and his relatives, but also it has 
considerable economic impacts on the health care system. Financial cost for AD screening, 
health care, hospice care and research are substantial. The World Health Organization (WHO) 
estimated the total costs of AD in the United States (USA) to be $ 1.75 billion for the year of 
2000 (“WHO | Chapter 2,” 2001). Analogously, it is projected that the total payments for AD and 
other dementias will escalate from $ 259 billion in 2017 to $ 1.1 trillion by 2050 (“Latest 
Alzheimer’s Facts and Figures,” 2013). 
   As life expectancy is increasing, the number of individuals living with this disorder is 
expected to soar. In 2000, the worldwide prevalence of AD for the 60-years-old and older 
population was 5% for men and 6% for women (“WHO | Chapter 2,” 2001). Comparably, this 
prevalence for the same population is estimated at 10 % in 2017 for the USA. Nonetheless, the 
prevalence of AD for the whole US population was 4.5 million in 2000, and this estimate is 
expected to rise to 13.2 million by 2050 (Andrawis et al., 2012). 
 Currently, there are still no specific markers to confirm AD diagnosis, nor effective 
treatment for AD, nor an established way to slow down the rate of degeneration. Progress in 
technology allow positron emission tomography (PET) and magnetic resonance imaging (MRI) 
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scan to determine the extent of brain impairment.  Nonetheless, the need for continuing efforts to 
slow down the progression, to cure, or to prevent AD is still crucial. This paper attempts to 
further explore the role of positive family history in glucose metabolism among at risk AD 
subjects. 
 
1.2 Alzheimer’s disease description  
The term Alzheimer’s disease has its origin back in 1906, when a German physician 
named Dr. Alois Alzheimer presented the case of a rare brain disorder to a meeting.  
He reported the case of a 50-year-old woman whom he had followed from her admission for 
memory loss, language problems, and unpredictable behavior, until her death 5 years later. The 
plaques and tangles identified from brain autopsy characterized what we call nowadays 
Alzheimer’s disease (Hippius & Neundörfer, 2003). 
Clinically, AD is characterized by continuing decline in memory, thinking and reasoning 
ability, disrupting daily activities. This disease is usually associated with two types of abnormal 
lesions found in the cerebral cortex: amyloid plaques and neurofibrillary tangles (NFT). Amyloid 
plaques, located between the neurons, are small and dense residues of a certain protein called 
beta-amyloid (A𝛽), while neurofibrillary tangles, located inside the neurons, are insoluble 
twisted fibers of a protein called tau. Depositions of protein from both amyloid plaques and NFT 
are part of normal aging process, but individuals with AD have far larger amount of these protein 
depositions.  Evidence suggests that plaques and tangles are necessary but not sufficient cause 
for developing AD, because both are also found in other dementia cases and in non-demented 
people. Large amount of A𝛽 depositions obstruct the brain and break connection with other 
nerve cells that play a critical role in memory and learning functions, leading to neural death.  
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Amyloid starts accumulating several years before the onset of AD clinical symptoms. It is 
estimated that neurodegeneration in AD starts around 20 to 30 years before clinical indication of 
its presence (Jagust, William, 2009). It is also documented that the regions of the brain most 
affected by the disease are found in the temporal lobes (MTL), specifically the hippocampus, 
entorhinal cortex, and subiculum (Jagust, William, 2009). Brain imaging can help detect and 
measure plaque and tangle load.   
 
1.3 Detection of Alzheimer’s disease with Positron Emission Tomography (PET) 
Research advancements in AD, specifically in neuroimaging, in the past decades made it 
possible to visualize the human brain during life using positron emission tomography (PET).  
The modality PET offers the capability to monitor AD-related changes in the brain in many 
views. However, the most widely used are Pittsburgh Compound B (PIB-PET) by tracking the 
burden of A𝛽 deposition in the brain, and flurodeoxy glucose (FDG-PET) by providing estimates 
of the cerebral metabolic rate of glucose (CMRglc). Those views are effective in depicting brain 
functional abnormalities.   
Amyloid PET scan helps identify both fibrillar amyloid detected in blood vessels 
(cerebral amyloid angiopathy) and interstitial fibrillar amyloid in plaques. Nevertheless, amyloid 
PET is limited in helping diagnose AD because of the prevalence of normal older individuals in 
whom amyloid deposition is found is high. The estimates for age-specific positivity rates for 
amyloid PET are less than 5 adults for every 100 adults aged between 50 and 60 years, 10 adults 
for every 100 adults aged between 60 to 70 years, 25 adults for every 100 adults aged between 
70 and 80 years, and more than 50 adults for every 100 adults aged between 80 to 90 years 
(Johnson et al., 2013). These high prevalences suggest that, although clinical symptoms of Aβ 
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are a risk factor for AD, they are not a sufficient cause of AD. Besides, these age-related 
prevalences provide evidence that amyloid detection may be related to age or other medical 
conditions.  
Conversely, FDG-PET studies have shown significant correlation between CMRglc 
reductions and AD symptoms severity. Thus, although normal aging is also characterized by 
CMRglc decline, hypo-metabolism is widely considered as a consistent in vivo AD biomarker 
(Jagust, William, 2009). Importantly, as glucose is known as the main source of energy for the 
brain, FDG-PET tool help depict medial temporal lobe (MTL) glucose metabolism at pre-
symptomatic stages of AD.  
 
1.4 Purpose 
In this study, I will examine the longitudinal effect of family history on cerebral 
metabolic rate of glucose in Mild Cognitive Impaired individuals. 
First degree family history is considered as the most conspicuous risk factor for 
developing AD, after advanced age (Jagust, William, 2009). However, researchers and clinicians 
still rely on subject self-report FH to ascertain this variable because the biological mechanism 
underlying the effects of FH on AD biomarkers are still not fully established (Lampert et al., 
2014). Besides, several studies suggest that AD brain changes have a lengthy period before 
clinical symptoms manifestations. Therefore, identifying how family history (FH) of 
Alzheimer’s disease affects the brain function through AD biomarker abnormalities will 
contribute to a better understanding and interpretation of those biomarkers. It will help better 
understand the brain change mechanisms at pre-symptomatic stages of AD, which will greatly 
improve clinical interventions regarding the disease.  
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Although considerable research has been devoted to evaluating the effects of positive 
family history on AD hallmarks, those studies are limited in several ways. First, most of those 
studies are cross-sectional, and do not assess the temporal effect of a positive family history and 
hypo-metabolism. Second, the few studies that used longitudinal analysis are limited by the 
relatively short period of subjects’ follow-up (less than 4 years). Finally, most of those studies 
used relatively small samples. Therefore, the purpose of this study is first to examine the effect 
of positive AD family history (FH+) on cerebral metabolic rate of glucose (CMRglc) over a 
period of 5 years on specific brain regions. Additionally, this study attempts to test whether there 
are parent gender effects on FDG-PET when the groups negative family history (FH-) vs paternal 
family history (FHp) vs maternal family history (FHm) are compared. This paper will also 
examine whether there is effect modification with Apolipoprotein E E4 Genotype (APOE4) 
interaction.  
 
1.5 Research Questions 
This study research questions are: Are there significant CMRglc differences between FH- 
and FH+ (maternal and paternal combined) groups? Does the interaction with APOE4 allele 
modify these results? Are the effects of maternal family history on CMRglc different from the 
effects of paternal family history on CMRglc when the groups FH- vs FHp vs FHm are 
compared? To answer these questions, it is hypothesized that: 
1) A positive FH would be associated with greater reduction of CMRglc in specific 
brain areas (Left and right Angular Gyrus, Bilateral Posterior Cingular, Left and 
right Inferior Temporal Gyrus). 
2) Positive APOE4 allele has effect modification on the association of posit ive family 
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history with CMRglc. 
3) Maternal history of AD would be associated with greater reduction of CMRglc in 
specific brain areas relative to that seen in groups of subjects with paternal or no 
parental history of AD. 
The reminder of this paper is organized as follows. Chapter 2 presents a literature review 
related to AD risk factors, and the association between positive AD family history and CMRglc.  
Chapter 3 describes the methods and procedures for the analyses. Chapter 4 reports the main 
findings and chapter 5 discusses the results and conclude.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Alzheimer’s disease risk factors 
It has been proven that the most common factors that increase the risk of developing 
Alzheimer’s are age, family history, and genetics. Nonetheless, recent advances suggest that 
there are other factors that need to be investigated. 
• Age 
Known as a gradual decline in cognitive functions, AD is mostly common among those 
who are 65 years old and more. The age-specific incidence rates for AD double for every six 
years of added life (Tanna, 2004). This implies that the more advanced in age an individual is, 
the higher is the risk for this person to develop AD. This effect is consistent across the literature 
(Adluru et al., 2014; Xiong et al., 2011; Honea, Swerdlow, Vidoni, & Burns, 2011). 
• Family history  
 Xiong et al., (2011) defined a person with positive FH for AD as someone with one 
or both biological parents with AD onset below 80 years old, and a person with negative FH as 
someone with both biological parents living to age 70 or greater without AD.  
 Studies report that early onset familial AD (FAD) represents less than 5 % of all AD 
cases (Jagust, William, 2009). Interestingly, Lampert and colleagues (2013) speculated that AD 
FH status is associated with earlier onset of AD pathology. Kennedy and colleagues (1995) 
reinforced these observations by reporting that global CMRglc reductions worsens along the 
course of the disease for individuals with positive AD family history.  Importantly, first degree 
family history is largely recognized as the second demographic AD risk factor. The risk for a 
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normal individual with an AD-affected parent is 4 to 10 times higher than a normal individual 
with no family history (FH-).  
• Apolipoprotein E E4 Genotype  
       Known to provide lipids throughout the central nervous system, APOE allele has three 
common isoforms which are APOE-2, APOE-3, and APOE-4. Every individual inherits a copy 
of the isoform from each of his/her parent. Individuals who inherit the APOE-4 (𝜀4) genotype 
have an increased risk of developing AD, even at a younger age than normal. Studies revealed 
that 40 out of every 100 AD persons have at least one APOE-4 allele (Jagust, William, 2009). In 
2013, Fleisher and colleagues examined the effects of APOE-4 gene and aging on florbetapir 
F18-PET. Their study demonstrated that cortical amyloid deposits start accumulating 20 years 
earlier in cognitively healthy APOE-4 carriers compared to non-carriers (Fleisher et al., 2013).  
 
2.2 CMRglc from FDG-PET and family history  
            The literature on the effects of family history on CMRglc is sparse. 
To describe the metabolic features of 3 AD-affected subjects and 1 unaffected 
individuals, all subjects having positive AD family history, A. M. Kennedy et al., (1995) used 
Statistical parametric mapping (SPM), and analysis of covariance (ANCOVA).  The 
investigators discovered that all cases showed hypo-metabolism in the parieto-temporal regions. 
These observations even were greater for the two severely affected patients.  These findings 
indicate that deficit in CMRglc aggravates along the course of the disease. Nonetheless, the use 
of a small sample size of 4 patients detract the relevance of these findings. 
 Kennedy et al., (1995) attempted to determine whether FDG-PET can help detect changes 
in CMRglc in a population of 24 cognitively normal individuals with positive AD family history 
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and 16 age-matched with no AD family history. For the at-risk group, Kennedy and colleagues 
found significant CMRglc reductions in the areas of parietal, temporal, and frontal cortices. This 
study provides evidence that asymptomatic individuals who are FH+ have metabolic deficit on 
PET. However, this study did not control for partial volume correction of glucose metabolism 
values. Normally, patients with AD show significant brain shrinkage on magnetic resonance 
imaging (MRI). Thus, the CMRglc reductions could be an effect of brain volume losses, or the 
effect of cerebrospinal fluid (CSF) in certain region of the brain. 
In 2006, Mosconi and colleagues addressed this limitation by comparing CMRglc and 
volumes in several regions of the brain for FH+ subjects and age-matched controls (Mosconi, 
Sorbi, de Leon, Li, & al, 2006). They considered the whole brain in their analysis. This study 
reports that asymptomatic FH+ individuals present global CMRglc reductions, and these effects 
of CMRglc on FDG-PET remain significant after correcting for partial volume from MRI. 
However, the authors used a cross-sectional analysis. This limits the study power in finding a 
significant difference because AD has a lengthy period of onset. Moreover, the investigators 
used a small sample size of 7 at risk individuals and 7 healthy controls.  
In another study, Mosconi et al., (2007) examined the FDG-PET of cognitively healthy 
elderly, comparing those with maternal, paternal and no AD family history. This study revealed 
that, compared to those with an AD-affected father and those who are FH-, individuals with 
maternal FH have greater CMRglc reductions in the same brain regions of affected AD subjects. 
These regions are posterior cingulate cortex/precuneus, parieto-temporal and frontal cortices, and 
medial temporal lobes.  Nevertheless, the authors recommended longitudinal investigations to 
determine whether the observed results predispose those with maternal FH to develop the 
disease. Another limitation of this study was the relatively small sample size.  
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Remarkably, through a longitudinal study, Mosconi et al., (2008) evaluated the effect of 
maternal history of AD on CMRglc using FDG-PET on 121 cognitively intact subjects. From the 
121 participants, 61 of them were considered in the longitudinal analysis (2 years of follow-up). 
This population was categorized as 35 with FH-, 8 with paternal FH+, and 18 with maternal 
FH+. There was no difference of CMRglc between paternal FH group and negative FH group. 
Conversely, the maternal FH group had greater CMRglc reductions when compared with 
paternal FH group and negative FH group. The researchers concluded that progressive CMRglc 
decline happens at middle age for those with maternal history of AD, and is even more severe for 
those crossing two generations of maternal grandmother AD history. The results of this study 
suggest that there is a transmitted maternal factor that impacts the brain pathophysiology of the 
offspring. Nevertheless, the relatively short period of subjects’ follow-up weakens the relevance 
of this study.  
A much more recent study evaluated the effects AD family history on glucose 
metabolism with FDG-PET using a population of 153 cognitively normal individuals among 
whom 29 were FH+ (Lee et al., 2016). Comparing the FH+ group with the FH- group, the 
authors did not found any differences in CMRglc in any cortical region of the brain, even after 
controlling for the effect of APOE ε4. 
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CHAPTER 3 
METHODS AND PROCEDURES 
3.1 Data source  
Data were drawn from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
database (adni.loni.usc.edu). The ADNI is a continuing multisite imaging longitudinal study 
across the U.S. and Canada currently with three phases: ADNI-1, ADNI-GO and ADNI-2. 
Starting on October 2004, the first phase last 5 years with 200 cognitively normal control, 400 
MCI, and 200 mild AD subjects. Participants were recruited by using advertisements and clinical 
referrals. More information regarding ADNI phase one study is provided in the procedures and 
protocol manual (Alzheimer’s Disease Neuroimaging Initiative, 2010).  
Figure 1:  Regions of interest  
 
(Landau & Jagust, 2009) 
This study’s outcome of interest (FDG-PET) is the mean glucose metabolism drawn for 
five different brain regions: Left and right Angular Gyrus, Bilateral Posterior Cingular, Left and 
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right Inferior Temporal Gyrus. The choice of these regions were based on the literature review as 
they demonstrated hypo-metabolism in AD patients (Landau & Jagust, 2009). 
 
3.2 Study design and population 
The analyses in this paper refer to ADNI phase-1 with the MCI population only. The 
choice of MCI population is justified by the fact that neurodegeneration starts several years 
before memory symptoms manifest, and MCI subjects is widely considered as being at higher 
risk of developing AD. Consequently, since MCI is recognized as a transitional phase into AD, it 
is expected that the MCI group near to the anticipated age at onset will provide a greater number 
of subjects in a pre-symptomatic stage of the disease which, in turn, will increases the power of 
the study to detect an effect. ADNI classified subjects as Mild Cognitive Impaired if they had 
subjective memory complaint, objective evidence of abnormal memory function, Mini-Mental 
State Examination (MMSE) score between 24 and 30, and Clinical Dementia Rating of at least 
0.5.  
Subjects’ exclusion criteria were: important neurologic disease other than AD; 
psychiatric disorder; alcohol dependency within the last 2 years; and clinical illnesses that could 
impair cognition or protocol compliance. An exhaustive list of inclusion and exclusion criteria is 
provided in the procedures and protocol manual (Alzheimer’s Disease Neuroimaging Initiative, 
2010). 
At the time the data were gathered, February 22nd 2017, a sample size of 177 subjects 
with a maximum of 30 observations per subject met the study inclusion criteria, establishing a 
total of 952 observations. Not all subjects had the same number of follow-ups and only 124 
subjects had baseline information available.  All missing observations for the independent 
variables were excluded in the study. Age and education are measured in years, and FH, APOE4 
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and gender are dichotomous variables.  These covariates were chosen based on the literature. 
Participants included in the study had a MMSE score between 24 and 30, aged between 57 and 
90 years old, with education level ranging from 8 to 20 years.  40 % were female and 49 were 
APOE4 carriers. There was a total of 8 observation time-points: the baseline interview and seven 
follow-up measurements (6, 12, 18, 24, 36, 48, and 60 months from baseline).  
 
 3.3 Statistical Analyses 
For all analyses, significance level is set at 0.05, unless stated otherwise. To test for baseline 
difference between FH+ and FH- groups for the continuous independent variables, the Wilcoxon 
rank-sum test had been used, because these variables are not normally distributed. To examine if 
there is baseline difference between FH+ and FH- groups for the categorical variables, the Chi-
square test was used. Additionally, to analyze the effects of FH on CMRglc, multivariate 
generalized linear mixed-effect models were used. This statistical approach will help assess 
factors influencing longitudinal glucose metabolism reduction in AD while accounting for 
variability in individual initial points. This approach also accounts for both within-subject 
variations and between-subject variability. Statistical analyses were carried out using SAS PROC 
MIXED (version 9.4). Three sets of mixed effects models were carried out. Model 1 assess if 
there are CMRglc differences between FH+ and FH- groups over time. Model 2 tests if APOE4 
effects modifies the results. Finally, model 3 examine if the effects of maternal family history on 
CMRglc are different from the effects of paternal family history on CMRglc when the groups 
FH- vs FHp vs FHm are compared. 
Model specification: 
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In the analyses, random intercept with random slope coefficient of Time models are 
estimated based on the assumption that subjects have different CMRglc lines with different 
starting points and CMRglc change over time. We also assume that the individual background 
variables (Age and Gender) may influence CMRglc, but their effects will not change over time. 
Only the effects of region and family history will change over time. 
Model 1: Effects of FH on CMRglc  
The level-one or the within-subject model is described as: 
CMRglcijt = β0ij + β1ij (Time)it + 𝜀𝑖𝑗𝑡 
and the level-two or the between-subject model takes the following form: 
β0ij =𝛽0 + 𝛽𝑅𝑒𝑔𝑖𝑜𝑛𝑗(Region)ji + 𝛽𝐴𝑔𝑒(Age)i + 𝛽𝐺𝑒𝑛𝑑𝑒𝑟(Gender)i + 𝛽𝐹𝐻(FH)i + 
𝛽𝐴𝑔𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗(Age*Region)ji + 𝛽𝐺𝑒𝑛𝑑𝑒𝑟∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗(Gender*Region)ji + 𝛾0𝑖 
and  
β1ij = βTime + 𝛽𝑇𝑖𝑚𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗 (Region)ji + 𝛽𝑇𝑖𝑚𝑒∗𝐹𝐻(FH)i + 𝛽𝐹𝐻∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗(FH*Region)ji +𝛾1𝑖 
The combined equation is: 
CMRglc𝑖𝑗𝑡=𝛽0+𝛽𝑅𝑒𝑔𝑖𝑜𝑛𝑗(Region)ji+ 𝛽𝐴𝑔𝑒(Age)i  + 𝛽𝐹𝐻(FH)i + 𝛽𝐺𝑒𝑛𝑑𝑒𝑟(Gender)i + 
𝛽𝑇𝑖𝑚𝑒(Time)it  + 𝛽𝐴𝑔𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗 (Age*Region)ji + 𝛽𝐺𝑒𝑛𝑑𝑒𝑟∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗(Gender*Region)ji + 
𝛽𝑇𝑖𝑚𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗 (Time*Region)jit + 𝛽𝐹𝐻∗𝑡𝑖𝑚𝑒(FH*Time)it + 𝛽𝐹𝐻∗𝑇𝑖𝑚𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗(FH*Time*Region)ijt 
+𝛾1𝑖(Time)t +𝛾0𝑖 + 𝜀𝑖𝑗𝑡 
 
CMRglc𝑖𝑗𝑡 designates the t
th occasion (t= 0, 6, …60 months) of glucose metabolism 
measure for the jth region (j=1, 2, …5) of the brain for the ith individual (1, 2, …177). β0i and β1i 
are respectively intercept coefficient and slope coefficient of (Time)it. They are both random 
regression coefficients suggesting that the initial level and the rate of change of glucose 
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metabolism measures will differ by subject. (Time)it is the time measurement occasion and  𝜀𝑖𝑗𝑡 
refers to the within-subject error coefficient. This error term accounts for variation in each 
subject’s repeated measurements over time. 𝜀𝑖𝑗𝑡 is assumed to follow a Gaussian distribution 
with mean zero and variance σ2. 
In level-two,  𝛽0 denotes the grand mean initial level of glucose metabolism for 
“Cingulum Post Bilateral” region for a 75 years old male with no FH of AD. βTime represents the 
average rate of change of glucose metabolism for the subjects with positive family history 
adjusting for individual-level covariates. βRegionj represents the fixed effects of region j on 
glucose metabolism with “Cingulum Post Bilateral” as reference. βFH is the difference in the 
average initial level of glucose metabolism between FH+ group and FH- group. βFH*time 
represents the difference in rate of change of glucose metabolism between FH+ group and FH- 
group. βAge and βGender are respectively fixed-effect of the individual-level predictors Age and 
Gender. 𝛾0𝑖  and  𝛾1𝑖 account for unknown error of the i
th individual on the level-1 random 
regression coefficients (β0i and β1i). Thus, they represent between-subjects error coefficients 
accounting for cross-individual variations in the effects of predictors’ rate-of-change on 
CMRglc. It is assumed that  𝛾0𝑖 and  𝛾1𝑖  are normally distributed with means zero and variances 
𝜎0
2  and 𝜎1
2 respectively, and covariance 𝜎01
2 . 
Model 2: Controlling for APOE4 
CMRglc𝑖𝑗𝑡=𝛽0+𝛽𝑅𝑒𝑔𝑖𝑜𝑛𝑗(Region)jit + 𝛽𝐴𝑔𝑒(Age)it + 𝛽𝐺𝑒𝑛𝑑𝑒𝑟(Gender)i + 𝛽𝐹𝐻(FH)i + 𝛽𝑇𝑖𝑚𝑒(Time)it 
+ 𝛽𝐴𝑃𝑂𝐸4(APOE4),i  + 𝛽𝐴𝑔𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗(Age*Region)jit + 𝛽𝐺𝑒𝑛𝑑𝑒𝑟∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗(Gender*Region)ji + 
𝛽𝑇𝑖𝑚𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗 (Time*Region)jit + 𝛽𝐴𝑃𝑂𝐸4∗𝑇𝑖𝑚𝑒(APOE4*Time),it + 𝛽𝐹𝐻∗𝑡𝑖𝑚𝑒(FH*Time)it + 
𝛽𝐹𝐻∗𝑇𝑖𝑚𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗(FH*Time*Region)ijt + 𝛽𝐴𝑃𝑂𝐸4∗𝑇𝑖𝑚𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗(APOE4*Time*Region)ijt 
+𝛾1𝑖(Time)t +𝛾0𝑖 + 𝜀𝑖𝑗𝑡  
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In model 2, the common terms have the same meaning as in model 1, except that baseline 
subject additionally possesses APO4- allele. The term 𝛽𝐴𝑃𝑂𝐸4 indicates additional baseline effect 
of APOE4+.  𝛽𝐴𝑃𝑂𝐸4∗𝑇𝑖𝑚𝑒 denotes the difference in rate of change of glucose metabolism 
between APOE4+ group and APOE4- group. 𝛽𝐴𝑃𝑂𝐸4∗𝑇𝑖𝑚𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛  represents the difference in rate 
of change of glucose metabolism between APOE4+ group and APOE4- group by brain region. 
Model 3: Effects of FH parenting on CMRglc 
CMRglc𝑖𝑗𝑡=𝛽0+𝛽𝑅𝑒𝑔𝑖𝑜𝑛𝑗(Region)ji+ 𝛽𝐴𝑔𝑒(Age)i  + 𝛽𝐹𝐻(FH)i + 𝛽𝐺𝑒𝑛𝑑𝑒𝑟(Gender)i + 
𝛽𝑇𝑖𝑚𝑒(Time)it  + 𝛽𝐴𝑔𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗 (Age*Region)ji + 𝛽𝐺𝑒𝑛𝑑𝑒𝑟∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗(Gender*Region)ji + 
𝛽𝑇𝑖𝑚𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗 (Time*Region)jit + 𝛽𝐹𝐻∗𝑡𝑖𝑚𝑒(FH*Time)it + 𝛽𝐹𝐻∗𝑇𝑖𝑚𝑒∗𝑅𝑒𝑔𝑖𝑜𝑛𝑗(FH*Time*Region)ijt 
+𝛾1𝑖(Time)t +𝛾0𝑖 + 𝜀𝑖𝑗𝑡 
  In model 3, the common terms have the same meaning as in model 1 as well. The only 
difference is that the variable FH has three categories: FH-, FHp, and FHm. 
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CHAPTER 4 
RESULTS 
 
4.1 Subject characteristics 
As summarized in table 1, there was not enough evidence to reject the null hypothesis 
regarding no differences between the FH+ and FH- in terms of age, gender, education, MMSE 
score and percent of APOE4. Thus, it is assumed that demographic and clinical factors do not 
differ between FH groups. Patients who had a parent with AD represent 25.8 % of the baseline 
sample. Of the participants with parental family history of AD, 65 % were APOE4 carriers. 
Among those who had no AD family history, 51 % were APOE4 carriers.  For both groups, the 
mean MMSE score was approximately 27, the mean years of education was around 16 and the 
mean age was roughly 75 years. The percent of females in the group with no FH is slightly 
higher than those in the other group, 34 % compared to 28 %.  
 
Table 1: MCI Subjects’ demographic and clinical characteristics at baseline by Family History 
status 
Characteristics FH+ FH- p-value 
n 32            92  
Age (mean)      74.96        75.86 0.3943 
Female %      0.28          0.34 0.4905 
Education (mean)    16.31         15.75 0.4460 
MMSE Score (mean)   27          27.25 0.5121 
APOE4 %       0.65            0.51 0.1761 
 
 It worth noticing that while the baseline sample size is 124, subjects were 
allowed to leave and enter the study at any time. Therefore, the total sample size in this analysis 
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is 177. Figure A1 illustrates the trend1 for CMRglc measurement occasions. On the other hand, 
figure 2 compares baseline CMRglc with FH status by brain region.  
 
Figure 2: Baseline Cerebral Metabolic of Glucose by brain region and FH status 
 
 Although some differences are modest, overall, subjects with positive FH 
showed lower CMRglc at baseline. 
 
4.2 Effect of FH on CMRglc 
Since having an age of 0 in the study is meaningless, the variable AGE has been centered 
around its mean (75 years). The intra-class correlation (ICC) for this model is 0.728 which 
means that 72.8 % of the total deviation is due to between-subject heterogeneity. ICC score also 
suggests that individual (level-2) variability is a much more important than random variations 
                                                 
1 See appendices. 
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between measurement occasions (level-1 variability). The global effect of brain region, time, 
age, and the interactions age by region, gender by region, and time by FH by region are all 
statistically significant. However, gender, FH and the interaction terms time by region and time 
by FH are not statistically significant. The estimated average initial glucose metabolism for the 
region “Cingulum Post Bilateral” for male subjects aged 75 years old in the FH- group is 1.292 
(p <.0001), and it is expected to change on average across occasions at a rate of -0.00265 (p 
<.0001). Nonetheless, while decreasing and statistically significant, the main effect of time is 
very low. The mixed effects model also showed that as age is increasing, total glucose 
metabolism is decreasing (-0.00896, p <.0001) for male with FH-.  
Interestingly, the main effect of FH (-0.019, p= 0.4987) shows that baseline glucose 
metabolism was slightly lower for FH+ subjects, compared to FH- participants although this 
difference is not statistically significant. This result confirms the observations in figure 2. 
Intriguingly, the rates of change for FH- subjects are positive for all regions, thus they are 
increasing. Still, this observation is statistically significant only for two regions: Angular Right 
(p=0.0012) and Temporal Right (p=0.008).  
 
Table 2: Effects of Family History on 5 years Cerebral Metabolic Rate of Glucose 
Regions FH- rate 
FH- rate 
SE 
FH- rate 
p-value 
Difference 
of FH+ rate 
FH+ rate 
difference SE 
FH+ rate 
difference 
p-value 
Angular Left 0.001183 0.000618 0.0559 -0.00127 0.000919 0.1692 
Angular Right 0.00215 0.000664 0.0012 -0.00252 0.000989 0.0111 
Temporal Left 0.000808 0.000676 0.2325 -0.0022 0.001 0.0281 
Temporal Right 0.001858 0.000699 0.008 -0.00306 0.001007 0.0025 
Cingulum PostBilateral ref.   ref.   
 
Regarding the effects of FH+ on CMRglc, the primary analysis revealed that, after 
controlling for the other covariates, FH effects for all brain region on glucose metabolism rate is 
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lower for FH+ participants compared to FH- subjects. These findings are all statistically 
significant, except for the region Angular Left (p=0.1692). The same models were fitted for each 
brain region separately, this approach leaded to the same findings. As a result, the mixed effects 
model shows that FH+ subjects present greater CMRglc decline over time compared to FH- 
subjects. 
 
4.3 Effect of FH on CMRglc after Adjusting for ApoE4 
Mixed effect model results for model 2 are shown in table 3. APOE4+ subjects had 
smaller glucose metabolism at baseline compared with APOE4- subjects, however these 
differences failed to reach statistical significance (-0.04705, p= 0.1263). Moreover, compared to 
non-carriers, APOE4 carriers presented smaller CMRglc for all the regions, although statistically 
nonsignificant. In short, there was not enough evidence to infer that APOE4 is a significant 
predictor of CMRglc either globally or for specific brain region.  
 
Table 3.- Effect of Family History on 5 years Cerebral Metabolic Rate of Glucose, adjusting for 
APOE4 allele 
Regions 
APOE4+ 
rate 
APOE4+ 
SE 
APOE4+ p-
value 
Difference 
of FH+ 
rate 
FH+ rate 
difference 
SE 
FH+ rate 
difference 
p-value 
Angular Left -0.00142 0.001195 0.2357 -0.00111 0.001017 0.2767 
Angular Right -0.00041 0.001303 0.7508 -0.00296 0.0011 0.0073 
Temporal Left -0.00258 0.001352 0.0566 -0.00229 0.00112 0.0414 
Temporal Right -0.00117 0.001372 0.3936 -0.00324 0.001121 0.004 
Cingulum PostBilateral ref.    ref.   
 
 
As in the previous model, FH+ subjects showed significantly lower glucose metabolism 
rate compared to FH- participants after additional control for APOE4. However, the model 
adjusting for APOE4 presented slightly greater decline than the model without APOE4. 
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Specifically, positive FH is associated with greater CMRglc decline over the 5-year period for all 
the region under study, except for “Angular Left” (p=0.2767). The results, after adding APOE4 
in the model with its interactions with brain region and time, indicates that heritability from FH 
status for describing CMRglc decline in MCI people is likely to be small but significant.  
 
 
4.4 Effect of Parental Family History on CMRglc 
Table 4 displays the results for model 3. Notably, as noticed in the previous models, FH+ 
status is associated with a lower decline of CMRglc over time compared to FH- status. However, 
this result is not statistically significant for any of the brain region when comparing three groups: 
FH- with maternal FH with paternal FH.  
 
Table 4: Effects of Parental Family History on 5 years Cerebral Metabolic Rate of Glucose 
Regions 
FHm rate 
difference  
FHm rate 
difference 
SE 
FHm rate 
difference 
p-value 
FHp rate 
difference 
FHp rate 
difference 
SE 
FHp rate 
difference 
p-value 
Angular Left -0.00182 0.001378 0.1862 -0.00123 0.001683 0.4644 
Angular Right -0.00172 0.001533 0.2615 -0.00247 0.00176 0.1605 
Temporal Left -0.00032 0.001491 0.8302 -0.00178 0.002031 0.3802 
Temporal Right -0.00241 0.001511 0.1106 -0.00148 0.00204 0.4698 
Cingulum PostBilateral ref.   ref.   
 
 
Contrary to what expected, subjects with paternal FH showed greater CMRglc decline 
when compared with FHm and FH- groups (-0.00246 p= 0.1847) although these differences did 
not reach statistical significance. Nonetheless, it is worth to remark that this study found no 
evidence of differences between parental FH groups. This might stem from a lack of statistical 
power in the sample because, while there were 131 subjects who are FH-, there were only 38 
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subjects with maternal history and 8 subjects with paternal history in the sample. Thus, this 
finding regarding parental FH is not reliable.  
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
 
5.1 Discussion of Research Questions  
The goal of this study was to assess if there is a difference on glucose metabolism rate 
from FDG-PET for selected brain regions between FH+ and FH- subjects while controlling for 
AD risk factors. This study also examined if there were parent gender effects on CMRglc. As 
hypothesized, there were greater and statistically significant CMRglc decline among FH+ 
participants compared to FH- subjects. This result aligns with prior studies (Angus M. Kennedy 
et al., 1995; Mosconi et al., 2006), and implies that neural function of subjects in FH+ group 
utilizes glucose at a higher rate than neural function of subjects in FH- group.  
Similar to previous finding, gender did not have a significant effect on glucose 
metabolism (Adluru et al., 2014). Conversely, hypo-metabolism was associated with age which 
is consistent across the literature (Xiong et al., 2011; Adluru et al., 2014). It was assumed that 
after adjusting for APOE4, effects of FH on CMRglc would be modified. But, the analyses 
showed that effects of FH on CMRglc remain significant and presented slightly greater decline 
when controlling for APOE4. 
It was hypothesized that participants with maternal history would show greater CMRglc 
decline compared to participants with paternal and those without FH. Strikingly, the results 
showed that subjects with paternal history had greater glucose metabolism rate decline than 
participants with maternal and FH- although nonsignificant. This finding is not in agreement 
with previous reports (Mosconi et al., 2007; Mosconi et al., 2008). This inconsistency may be 
due to differences in the type of population considered in the study (healthy subjects, MCI, or 
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AD), brain regions included, sample size, period of the study, covariates included, etc. This 
might also result from grouping bias since the groups maternal and paternal history were very 
small compared to the group of FH-. Nonetheless, it is worth noticing that others have also found 
no effect of FH on CMRglc (Lee et al., 2016). 
 
5.2 Study Strengths and Limitations  
 To our knowledge, no previous studies have considered MCI subjects to investigate the 
effects of FH+ on CMRglc over such a long period. Another strength of this study is the use of a 
relatively large sample size drawn from a well-established ongoing cohort study (ADNI). Using 
the multilevel linear regression model present many advantages also. This approach helps 
account for unbalanced data structures; it allows the use of all available observations from each 
subject; it has greater statistical power when applied to the same data; and it assess the within-
subject variations and the between-subject variability simultaneously. 
              However, this study presents also some limitations. Firstly, FH status was ascertained 
via subjects’ self-report or their study partners’ report. It is thus possible to have report bias in 
the sample due to uncertainty about parental AD history, denial, or unawareness due to early 
parental death, etc. Secondly, this study models did not control for partial volume from MRI. It 
has been established that AD at risk subjects present significant brain volume loss on MRI 
(Jagust, William, 2009). Therefore, it is possible that CMRglc reductions were an effect of brain 
shrinkage in the regions under study. Thirdly, the study sample size is limited and lack statistical 
power to detect the true differences between maternal history and paternal history and negative 
FH. The groups FHm and FHp might be under represented. Finally, using a multilevel modeling 
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approach, all subjects with at least one measurement observations were included in the analysis. 
Considering participants with at least 2 follow-up visits might have improved the model. 
 
5.3 Implications of Findings 
The mechanism explaining the effects of FH status is still not completely established and 
diverge depending of AD biomarkers. Subsequently, the contribution of examining the effect of 
FH on CMRglc over time is twofold. First, it characterizes the course of glucose metabolism in 
the brain at asymptomatic AD stages. Second, it shows that heritability from FH status for 
defining CMRglc decline in MCI people is small but statistically significant. These results 
extend the findings of previous research and imply that prevention interventions regarding AD 
could focus on the pre-symptomatic group ‘‘MCI subjects with FH+ aged between 57 and 90 
years”. Potentially, these findings could also facilitate drug development for AD at risk people. 
 
5.4 Future research direction  
Future research could further explore these results comparing, with the same approach, 
the three groups: Normal Cognitive (NC), MCI and AD subjects. Moreover, further analyses on 
this topic could test parental versus siblings AD history. Besides, replicating these models while 
controlling for partial volume correction would be interesting. 
 
5.5 Conclusion 
           In summary, this study found that subjects with positive FH presented greater CMRglc 
decline over the 5-year period. Thus, positive FH is associated with higher reduction of glucose 
metabolism rate. Furthermore, the analyses showed that APOE4 is not a significant predictor of 
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CMRglc. This suggest that, independent of APOE4, heritability from FH status for explaining 
CMRglc diminution in MCI people is small but significant. Finally, there was not enough 
evidence to detect any parental FH differences. Nevertheless, more research is needed to fully 
characterize the mechanism underlying the effect of FH status on AD biomarkers. 
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APPENDICES 
 
Figure A1: Observed individual CMRglc over five years 
 
 The linear relationship does not hold across all the subjects and the slopes vary across all 
the subjects. 
 
Figure A2: Observed individual CMRglc and overall estimated trend of CMRglc over five years 
by FH status 
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Figure A3: Observed individual glucose metabolism levels and the regression of CMRglc over 
five years by FH status 
 
 
 
Figure A4: Fitted individual growth CMRglc lines 
 
 The individual growth lines vary differently with individual intercepts and slopes. 
Some of the individual growth lines slope upwards, some slope downward and others are nearly 
flat. 
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Figure A5: Individual and average change trajectory from OLS regression by FH status 
 
 
